Literature DB >> 9669284

Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin.

A Zielke1, S Tezelman, G H Jossart, M Wong, A E Siperstein, Q Y Duh, O H Clark.   

Abstract

Hürthle cell carcinomas (HCC) of the thyroid are a variant of follicular thyroid tumors. In contrast to follicular thyroid carcinoma, HCC rarely take up radioiodine and frequently metastasize to the lymph nodes. Histologically they are indistinguishable from Hürthle cell adenomas except for evidence of invasion and metastasis. How these carcinomas develop and why they behave differently than other follicular tumors is not known. Although some differentiated thyroid cancer cell lines exist, none are from Hürthle cell tumors. We have established a well-differentiated thyroid cancer cell line from a metastasis of a HCC, designated XTC.UC1. In vitro, XTC cells display epitheloid morphology, grow with a population doubling time of 4.3 +/- 0.3 days, migrate, and invade through reconstituted basement membranes. The cells are immunoreactive for and release thyroglobulin, respond to thyrotropin (TSH) with increase of intracellular cyclic adenosine monophosphate (cAMP), proliferation, and invasion of reconstituted basement membrane, thus exhibiting characteristics of well-differentiated thyroid carcinoma. In vivo, xenografted XTC cells grow with a doubling time of 9.8 +/- 0.8 days. Tumors spontaneously metastasize to the lymph nodes and less frequently to the lungs and the liver. The cells retained their differentiated function in vivo as assessed by human thyroglobulin (hTG) secretion and immunohistochemistry. This is a first report of the establishment of a unique, highly differentiated thyroid carcinoma cell line derived from an HCC. Based on the ability to invade through reconstituted basement membrane in vitro and the potential to metastasize in vivo, this cell line may provide a unique model to study invasion and metastazation of well-differentiated thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669284     DOI: 10.1089/thy.1998.8.475

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  21 in total

1.  Functional analysis of three novel cell lines derived from human papillary thyroid carcinomas with three different clinical courses.

Authors:  Mayumi Ishikawa; Toshiaki Tachibana; Hisashi Hashimoto; Junko Toyomura; Toshihide Ito; Kumiko Tsuboi; Kazutoshi Shibuya; Takahisa Hirose; Shiro Minami; Gen Yoshino
Journal:  Hum Cell       Date:  2014-02-25       Impact factor: 4.174

Review 2.  Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR.

Authors:  Pan Deng; Cole M Haynes
Journal:  Semin Cancer Biol       Date:  2017-05-10       Impact factor: 15.707

3.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

4.  Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

Authors:  Michael W Yeh; Jean-Philippe Rougier; Jin-Woo Park; Quan-Yang Duh; Mariwil Wong; Zena Werb; Orlo H Clark
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

5.  Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes.

Authors:  E Allìa; P Cassoni; T Marrocco; M Volante; B Bussolati; M Wong; O H Clark; M Papotti
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

6.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 7.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

Review 8.  Relevance of mitochondrial genetics and metabolism in cancer development.

Authors:  Giuseppe Gasparre; Anna Maria Porcelli; Giorgio Lenaz; Giovanni Romeo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

9.  Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro.

Authors:  L Lan; D Cui; Y Luo; B Y Shi; L L Deng; G Y Zhang; H Wang
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

10.  Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors.

Authors:  Giuseppe Gasparre; Anna Maria Porcelli; Elena Bonora; Lucia Fiammetta Pennisi; Matteo Toller; Luisa Iommarini; Anna Ghelli; Massimo Moretti; Christine M Betts; Giuseppe Nicola Martinelli; Alberto Rinaldi Ceroni; Francesco Curcio; Valerio Carelli; Michela Rugolo; Giovanni Tallini; Giovanni Romeo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.